NCT01953328
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
See it on ClinicalTrials.gov ↗404 people
39.6%
60.4%
160 womenmiddle line = equal numbers244 men
- Phase
- PHASE3
- Paid for by
- Amgen
- Finished
- 2014-06
- Health conditions
- Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
- Who could join
- Anyone
- Ages
- 20 Years – 85 Years
- Average age
- mean 61.3 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Asian 100% · American Indian / Alaska Native 0% · Black / African American 0% · Native Hawaiian / Pacific Islander 0% · White 0%
Women left out
No rules that kept women out were found.
Study titles and rules are shown in their original English.